PB0062 - Extracellular Vesicles As Markers of Inflammation and Hypercoagulability during the First Month of Sars-COV-2 Infection in Outpatients and Hospitalized Patients.

Sunday, June 25, 2023

18:30 – 19:30 ET

Room: Exhibition

Presenting Author(s)

Barbara G. Barion (she/her/hers)

Postgraduate student
University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil

Co-Author(s)

TR

Tania R. F. da Rocha

Head of Hemostasis and Thrombosis Laboratory
Clinics Hospital of the University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
PV

Paula R. Villaça

Hematologist
Clinics Hospital of the University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
HY

Ho Yeh Li

Hematologist
Clinics Hospital of the University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
BM

Bruna Mazetto

Biologist
University of Campinas
Campinas, Sao Paulo, Brazil
EO

Erica Okazaki

Hematologist
Clinics Hospital of the University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
CR

Cynthia Rothschild, Master (she/her/hers)

Hematologist
ICESP - University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
BS

Bianca Stefanello

Hematologist
Clinics Hospital of the University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
VR

Vanderson Rocha

Hematologist
Clinics Hospital of the University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
FO

Fernanda A. Orsi

Hematologist
University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil

Background: Microvesicles (MVs) are potentially associated with COVID-19 associated coagulopathy.

Aims: Our aim was to identify the moment during the course of the disease when the stimulus for MVs release occurs and whether this is associated with disease severity.

Methods: We evaluate changes in MVs markers levels during the first month of COVID-19 in patients with severe disease as compared to outpatients, and their association with CRP and D-dimer levels. Blood samples were collected on three occasions: before the 10th day of symptoms , in the third week of symptoms and in the fourth week of symptoms for the quantification of the following MVs markers: CD41A, CD162, CD31 and CD142. Statistical tests of ANOVA with repeated measures were used.

Results: 85 patients were included, 65 outpatients and 20 ICU patients. Forty-three were men (51%), with a median age of 41 years old. The concentration of MVs expressing CD31+, CD41+, CD162+ and CD142+ were persistently elevated in ICU patients as compared to outpatients. There were no significant changes in the concentration of MVs during the course of the disease within the groups. In the third week of symptoms, D-dimer levels were correlated with MV-CD31+ (r=0.52; P< 0.0001), MV-CD162+ (r=0.35, P=0.001), MV-CD41A+ (r=0.44, P< 0.0001) and MV-CD142+ (r=0.47, P< 0.0001). CRP values from the third week of symptoms were correlated with MV-CD31+ (r=0.56, P= < 0.0001), MV-CD162+ (r=0.48, P< 0.0001), MV-CD41A+ (r= 0.41, P=0.0001), and MV-CD142+ (r=0.56, P< 0.0001). In the fourth week of symptoms, these correlations remained unchanged.

Conclusion(s): In conclusion, MVs that express antigens related to platelet activation, leukocyte-platelet interaction, endothelium-platelet interaction and tissue factor are released early during the course of severe COVID-19, coinciding with changes in inflammatory and coagulation markers.